Claudia Ordonez - 11 May 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Medical Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
11 May 2021
Net transactions value
-$49,670
Form type
4
Filing time
13 May 2021, 16:37:39 UTC
Next filing
15 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $480 +1,000 $0.4800* 1,000 11 May 2021 Direct
transaction KROS Common Stock Sale $50,150 -1,000 -100% $50.15 0 11 May 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -1,000 -1% $0.000000 99,211 11 May 2021 Common Stock 1,000 $0.4800 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.